London
23 °C
Manchester
26 °C
Glasgow
Dublin
18 °C
Belfast
Washington
Denver
23 °C
Atlanta
Dallas
Houston Texas
New Orleans
El Paso
Phoenix
Los Angeles
11 °C
-10 °C
25 °C
12 °C
22 °C
Moderna announces positive results for Omicron vaccine / Photo: © AFP
NYSE - LSE
| CMSC | 0.41% | 22.15 | $ | |
| CMSD | 0.13% | 22.37 | $ | |
| RBGPF | 3.48% | 65.27 | $ | |
| SCS | 3.9% | 10.885 | $ | |
| RIO | 2.13% | 61.285 | $ | |
| JRI | -0.15% | 12.96 | $ | |
| BCE | -0.82% | 22.525 | $ | |
| BCC | 4.73% | 93.02 | $ | |
| NGG | -4.54% | 67.62 | $ | |
| RELX | -4.34% | 51.61 | $ | |
| RYCEF | -1.35% | 10.36 | $ | |
| GSK | 2.12% | 37.415 | $ | |
| BP | 1.34% | 30.175 | $ | |
| BTI | -2.06% | 40.8 | $ | |
| VOD | -2.42% | 9.08 | $ | |
| AZN | 1.9% | 68.88 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
D.Czajkowski--GL
